The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
MRI contrast agents: Classification and application (Review)
Open accessAbstract
Magnetic resonance imaging (MRI) contrast agents are categorised according to the following specific features: chemical composition including the presence or absence of metal atoms, route of administration, magnetic properties, effect on the magnetic resonance image, biodistribution and imaging applications. The majority of these agents are either paramagnetic ion complexes or superparamagnetic magnetite particles and contain lanthanide elements such as gadolinium (Gd3+) or transition metal manganese (Mn2+). These elements shorten the T1 or T2 relaxation time, thereby causing increased signal intensity on T1-weighted images or reduced signal intensity on T2-weighted images. Most paramagnetic contrast agents are positive agents. These agents shorten the T1, so the enhanced parts appear bright on T1-weighted images. Dysprosium, superparamagnetic agents and ferromagnetic agents are negative contrast agents. The enhanced parts appear darker on T2-weighted images. MRI contrast agents incorporating chelating agents reduces storage in the human body, enhances excretion and reduces toxicity. MRI contrast agents may be administered orally or intravenously. According to biodistribution and applications, MRI contrast agents may be categorised into three types: extracellular fluid, blood pool and target/organ-specific agents. A number of contrast agents have been developed to selectively distinguish liver pathologies. Some agents are also capable of targeting other organs, inflammation as well as specific tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inorganic Nanoparticles for MRI Contrast Agents
Na, H. B., Song, I. C., & Hyeon, T. (2009) · Advanced Materials · doi:10.1002/adma.200802366 · Cited by 1,781
Jung, C. W., & Jacobs, P. (1995) · Magnetic Resonance Imaging · doi:10.1016/0730-725x(95)00024-b · Cited by 622
Classification and basic properties of contrast agents for magnetic resonance imaging
Geraldes, C. F. G. C., & Laurent, S. (2009) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.265 · Cited by 541
Manganese‐enhanced magnetic resonance imaging (MEMRI): methodological and practical considerations
Silva, A. C., Lee, J. H., Aoki, I., & Koretsky, A. P. (2004) · NMR in Biomedicine · doi:10.1002/nbm.945 · Cited by 486
Lin, Y., & Koretsky, A. P. (1997) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910380305 · Cited by 485
MS-325: albumin-targeted contrast agent for MR angiography.
Lauffer, R. B., Parmelee, D. J., Dunham, S. U., Ouellet, H. S., Dolan, R. P., Witte, S., McMurry, T. J., & Walovitch, R. C. (1998) · Radiology · doi:10.1148/radiology.207.2.9577506 · Cited by 457
Computed Body Tomography with MRI Correlation.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-824_3 · Cited by 348
Modification of human red cells by virus action; agglutination by incomplete Rh antibody.
CHU, C. M., & Coombs, R. R. A. (1947) · PubMed · Cited by 341
Bourrinet, P., Bengele, H. H., Bonnemain, B., Dencausse, A., Idee, J.-M., Jacobs, P. M., & Lewis, J. M. (2006) · Investigative Radiology · doi:10.1097/01.rli.0000197669.80475.dd · Cited by 339
Tissue-specific MR contrast agents
Weinmann, H.-J., Ebert, W., Misselwitz, B., & Schmitt-Willich, H. (2003) · European Journal of Radiology · doi:10.1016/s0720-048x(02)00332-7 · Cited by 250
Cited by
Dushyantha, N., Batapola, N., Ilankoon, I. M. S. K., Rohitha, S., Premasiri, R., Abeysinghe, B., Ratnayake, N., & Dissanayake, K. (2020) · Ore Geology Reviews · doi:10.1016/j.oregeorev.2020.103521 · Cited by 687
Advances in the Early Diagnosis of Hepatocellular Carcinoma
Wang, W., & Wei, C. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.01.014 · Cited by 492
Biomarkers in Cancer Detection, Diagnosis, and Prognosis
Das, S., Dey, M. K., Devireddy, R., & Gartia, M. R. (2023) · Sensors · doi:10.3390/s24010037 · Cited by 383
Rezaei, B., Yari, P., Sanders, S. M., Wang, H., Chugh, V. K., Liang, S., Mostufa, S., Xu, K., Wang, J., Gómez‐Pastora, J., et al. (2024) · Small · doi:10.1002/smll.202304848 · Cited by 366
Cancer‐Associated, Stimuli‐Driven, Turn on Theranostics for Multimodality Imaging and Therapy
Li, X., Kim, J., Yoon, J., & Chen, X. (2017) · Advanced Materials · doi:10.1002/adma.201606857 · Cited by 362
Stimuli-Responsive Polymer-Based Nanosystems for Cancer Theranostics
Wei, D., Sun, Y., Zhu, H., & Fu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.3c06019 · Cited by 303
A Comprehensive Review of Magnetic Nanomaterials Modern Day Theranostics
Gul, S., Khan, S. B., Rehman, I. U., Khan, M. A., & Khan, M. I. (2019) · Frontiers in Materials · doi:10.3389/fmats.2019.00179 · Cited by 297
Doped Zinc Oxide Nanoparticles: Synthesis, Characterization and Potential Use in Nanomedicine
Carofiglio, M., Barui, S., Cauda, V., & Laurenti, M. (2020) · Applied Sciences · doi:10.3390/app10155194 · Cited by 262
Magnetic Iron Nanoparticles: Synthesis, Surface Enhancements, and Biological Challenges
Vargas-Ortiz, J. R., Gonzalez, C., & Esquivel, K. (2022) · Processes · doi:10.3390/pr10112282 · Cited by 62
Tomitaka, A., Vashist, A., Kolishetti, N., & Nair, M. (2023) · Nanoscale Advances · doi:10.1039/d3na00180f · Cited by 45
Applications and Efficacy of Iron Oxide Nanoparticles in the Treatment of Brain Tumors
Varalli, L., Berlet, R., Abenojar, E., McDaid, J., Gascoigne, D. A., Bailes, J., & Aksenov, D. P. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040499 · Cited by 23
Metadata
- Authors
- Xiao, Y.-D., Paudel, R., Liu, J., Ma, C., Zhang, Z.-S., & Zhou, S.-K.
- Venue
- International Journal of Molecular Medicine
- Publisher
- Spandidos Publications
- Published
- 2016-09-21
- Volume
- 38
- Issue
- 5
- Pages
- 1319-1326
- ISSN
- 1107-3756 (ISSN-L)
- 1791-244X
- OpenAlex
- W2523155661
- Cited by
- 509
- References
- 35
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.